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Perfusion of rat hvers wtth polyvanadate, but not metavanadate. was found to mcrease m plasma membrane and decrease m cytosol protem kmase 
C activity. stmtlar to that obtamed with phenylephrme, an a-adrenergtc agonist The effect was prevented by phenoxybenzamine. but not by propra- 
nolo1 tmphcatmg r-adrenergic receptor activation Compartson of crystal structures of decavanadate and nonadrenaline revealed the occurrence 
of a structural feature of O*+(N) with distances of 5 5 A and 2.9 A 
Decavanadate: Protein kinase C; z-Adrenergtc agomst 
1. INTRODUCTION 
A variety of physiological processes and metabolic 
reactions are affected on treatment of animals or cells 
with salts of vanadium, known to be an essential trace 
element in some organisms (reviewed in [l-3]). 
Vanadate is found to mimic activities of noradrenaline 
of increase in the concentration of cyclic AMP in intact 
cardiac muscle [4], of contraction pulmonary artery 
[5], and of reduction of muscle tension [6]. It is not 
known whether such actions are obtained through ac- 
tivation of adrenergic receptors. Noradrenaline and 
adrenergic agonists are now established to act through 
a-adrenergic receptor for mobilization of intracellular 
pools of calcium resulting in its decrease in mitochon- 
dria and increase in cytosol in experiments with rat liver 
with isolated hepatocytes [7] or by perfusion [S]. The 
changes in calcium concentrations are accredited with 
the metabolic responses of activation of a-adrenergic 
receptor (reviewed in [9]). 
We reported that intraperitoneal treatment of rats 
with noradrenaline [lO,l l] or decavanadate [12] show- 
ed a number of effects on hepatic mitochondria, in- 
cluding increases in activities of a-glycerophosphate 
dehydrogenase and substrate-dependent Hz02 genera- 
tion. Increase in calcium-dependent respiration, deple- 
tion of mitochondrial calcium and decrease in pyruvate 
dehydrogenase activity, known to occur on activation 
of cu-adrenergic receptors [13,14], also were obtained 
on treatment with decavanadate [ 151. Under these con- 
ditions, the concentration of cytosolic calcium increas- 
ed due to inhibition of plasma membrane CaZf-ATPase 
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by vanadate [16], preventing its exit from the cells. 
These vanadate-induced changes were also obtained in 
sympathectomized animals excluding the possibility of 
intervention of endogenous noradrenaline, but were 
prevented by phenoxybenzamine, an cu-adrenergic 
blocking agent. Vanadate added in vitro had no effect 
on these mitochondrial activities. Since its concentra- 
tions did not build up in the tissue under the experimen- 
tal conditions, the action of vanadate is considered to 
be at the level of plasma membrane as a possible 
agonist of cu-adrenergic receptor. We now show that the 
intracellular changes in protein kinase C are obtained 
on perfusion of livers with decavanadate, similar to 
phenylephrine, an a-adrenergic agonist. 
2.. MATERIALS AND METHODS 
Male albino rats (120-130 g) of the Wistar strain were anaesthetiz- 
ed wtth ethyl ether and the livers were perfused with 0.25 M sucrose 
at 37°C in a non-circulating mode at a flow rate of 4 ml/min. 
Decavanadate (50pM) and other compounds were added to the 
sucrose solutton where indicated. The liver blanched in about 2 mm 
and perfusion was continued for the time periods indicated. The slow 
rate of perfusion wtth unbuffered sucrose ensured removal of blood 
from the organ wtthout affecting the structural integrity of 
rubcellular organelles and avoided any possible salt effects. 
Ltver plasma membrane vesicles were prepared by the method of 
centrifugatton on Percoll gradient described by Prpic et al. [17]. The 
membrane fraction identified by 5 ’ -nucleotidase activity (560 nmol 
AMP hydrolyzed/min per mg protein) was washed twice with 0.25 M 
sucrose containing Trts buffer (50 mM, pH 8.0), and suspended in 
Tris buffer (50 mM, pH 8.0), containing glycerol (10% w/v) and 
Triton X-100 (0.05% w/v) and stirred for 1 h in an ice-bath. The mix- 
ture was centrifuged at 15000 x g for 30 mm and the supernatant 
fraction was used for the assay of protein kinase C as described by 
Kikkawa et al. [18] by measuring the Cazc-dependent transfer of j2P 
from [-,-32P]ATP to histone Hi in the presence of phosphatidyl serine 
and diglyceride. 
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Fig. I. Ltver5 were perfused with 0.25 M sucrose [at 37°C) for 5 mm 
in all the cases. Where mentioned, the medium contarned 
phenylephrine (1 &%tl) (A) or decavanadate iSO,&ILI) (B). The 
adrenergic blocking agent<, phello~sb~nzarn~ne [PB(ru)] (C) or 
propranoiol [PR@)J (D), uere mcluded along with decavanadate at 
a concentratron of 70 mg/ml. Plasma membrane and cytosol 
fractions were prepared and assayed for the activity of protein kInabe 
C. The values of calcium-dependent activity expressed as pmoles of 
“P transferred from [?-“P]ATP to histone HI:min per mg plasma 
membrane prutem, are mean> and SD of mciependcnt determinations 
of liver5 of 4 rats m each group. The changes in a11 the cases except 
Decavanadatc war, prepared by Wring excess VZO~ in 0.3 M 
NaOH for 12 h. The filtered orange-yellow solution (pH 7) contamed 
predommantly the deca-form (a, judged hg NMR) and i? taken to be 
eqmvalent to 0 05 M concentration of N~~VI&ZX. 
3. RESULTS 
One of the we~~-~hara~ter~~~d events of activation of 
a-adrenergic receptor is the increase in the plasma 
membrane and the decrease in cytosol of the activity of 
Ca’+- and lipid-dependent protein kinase C (reviewed 
in [19]). Brief perfusion of livers for 5 min with 
decavanadatc mimicked the effect of the ru-adrenergic 
agonist, p~eny~ephrine, in redistributing the activities 
of protein kinase C in plasma membrane and in cytosof 
(Fig.1 A and F3). In other experiments (data not shown) 
increase in perfusion with decavanadate For 10 min 
produced further increase in plasma membrane activity 
and the effect was not obtained with metavanadatc 
(IOO~M). The data on preventing these effects by 
phenoxybenzamine, an cu-adrencrgic blocking agent, 
but not by propranolof, a Badrenergic blocking agent, 
when added in the perfusion medium along with 
polyvanadate (Fig.iC and D) are consistent with 
membrane-level of action of polyvanadate in activating 
the a-adrenergic receptor. 
D E C A’dA I\1 A DAT E NORADRENALINE 
Fig. 2. Comparlcon of structures of deca\anadate and noradrenahne. 
The structures were adapted from crystal Wuctures gl\en by E\anF 
Jr. [X] for decavanadate and bq Carlstram and BergIn [21] for 
noradrenahne The atom4 are marhed within the circleq by V, C. N 
and open for vanadrum, carbon, mtrogen and oxygen, respectlrel). 
The approxxnate distances bet\reen the atoms 0-O and O-N 
marked along the broken lines are obtained from the drstances and 
angles provided in the tuo references. 
It is puzzling to see how the two unrelated chemical 
compounds, noradrenaline, a catecholamine, and 
decavanadate, an inorganic polymer, can produce 
similar effects at the plasma membrane level. It is im- 
plicit that the two active compounds are interacting 
with an appropriate domain of the receptor protein. 
We therefore searched for a common structural feature 
in them. The only apparent structural feature in 
decavanadate is the presence of oxygens linked to 
vanadium in three ways: V=O, V-OH or V-O-V. In 
noradrenaline, the me&-position ring oxygen and the 
side-chain oxygen and nitrogen seem to be essential, 
but not the para-position ring oxygen, absent in the ac- 
tive agonist, pheny~ephr~~le. On comparison OF the 
crystaf structures of decavanadate f2O] and 
noradrenaline [21], we found the presence of two ox- 
ygens at about 5.5 A and of a third oxygen or nitrogen 
at about 2.9 A from one of the above oxygens, shown 
by dotted lines in Fig. 2. The formation of these three 
oxygens in decavanadate, not existing in the inactive 
monomer, is made possible because of polymerization 
to the cage-like structure characteristic of decavanadate 
f2Of. Admittedly, there is no proof that this three atom 
configuration of O-O-O(N) makes these molecules ac- 
tive but there is little else structurally that these 
molecules offer. 
4. DlSCUSSION 
To the list of many effects of vanadate treatment of 
whote animals or cells we have added the redistribution 
of intracellular calcium and protein kinase C activity, 
the two characteristic effecters of signal transduction in 
94 
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a-adrenergic stimulation [9]. We are encouraged by 
these results to suggest that vanadate in polymeric, but 
not monomeric, form is able to act directly on the liver 
plasma membrane as an agonist of cu-adrenergic 
system. This explains in some measure the multiplicity 
of its effects. A number of other direct actions of 
vanadate on plasma membrane-associated enzyme 
systems are known: inhibition of Na,K-ATPase [22], 
CaZf -ATPase [ 16,231, and 5 ’ nucleotidase [ 11; stimula- 
tion of adenyl cyclase [24,25], phosphorylation of pro- 
tein 1261 and protein-tyrosine 1271 and 
phosphatidylinositol [28]; and interaction with 
transducin of the visual excitation system [29]. Another 
example of selective action of decavanadate on plasma 
membrane is the stimulation of NADH oxidation ac- 
companied by oxygen reduction to Hz02 [30,31]. The 
relationship between these two decavanadate-specific 
reactions is not known. Selective oxidative modifica- 
tion of the regulatory domain of protein kinase C by 
H202, both activation and inactivation depending on 
concentration, has been recently reported [32]. Would 
Hz02 become a link between the two actions and thus 
participate in signal transduction? 
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